On February 3, 2025, BioNTech SE completed the acquisition of Biotheus, a clinical-stage biotechnology company focused on developing antibodies for oncological and inflammatory diseases.
AI Assistant
BIONTECH SE
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.